Estoppel in Ex Parte Reexam: Statutory Limits and Strategic Use

Ex parte reexamination does not generate estoppel in the way inter partes review does. There is no 315(e) bar after a final disposition. There is no statutory limit on raising the same grounds in district court that were raised at the USPTO. The procedural absence of estoppel is one of the structural reasons reexam has surged in 2025. But "no estoppel" is not the same as "no consequences." The reality is more textured.

What 315(e) covers and ex parte reexam doesn't

35 U.S.C. 315(e) creates estoppel after inter partes review. A petitioner who reaches a final written decision in IPR is barred, in any subsequent USPTO proceeding, district court action, or ITC investigation, from raising any ground that was raised or "reasonably could have been raised" during the IPR. The statute is intentionally broad.

Ex parte reexamination has no corresponding statutory estoppel. 35 U.S.C. 305 governs reexam procedure but does not impose estoppel. There is no bar on the third-party requester raising the same grounds in another forum after a reexam concludes.

What that means for challengers

The structural appeal for a third-party challenger considering a parallel-track invalidity strategy:

• Reexam concludes with claims confirmed → challenger can still attack the same patent in district court on the same grounds.
• Reexam concludes with claims amended or canceled → challenger gets the benefit without locking in a downstream limitation.
• Reexam denied at the SNQ stage → no estoppel anywhere; challenger pursues district court invalidity without procedural baggage.

Compare to IPR: a petitioner who reaches a final written decision is locked in. The post-IPR district court invalidity case has to use different prior art or different grounds. Ex parte reexam preserves the optionality.

What that means for patent owners

The absence of statutory estoppel is also why a reexam outcome does not give a patent owner the same insulation that an IPR final written decision provides. An IPR survivor cannot face the same prior art in district court. A reexam survivor can.

That said, the practical weight of a reexam certificate in district court is not zero. The certificate is admissible. The procedural history is admissible. Judges and juries treat USPTO review as evidence of patentability, even where the legal effect is informal.

Estoppel-adjacent doctrines that do apply

A few related doctrines can constrain post-reexam litigation behavior:

• Issue preclusion (collateral estoppel) may apply where the same issue was actually litigated and decided in the reexam. The doctrine is fact-specific and rarely operates as a clean bar.
• Judicial estoppel may apply where a party takes inconsistent positions across forums.
• Prosecution history estoppel continues to constrain claim construction. Statements made during a reexam, including by the patent owner in response to office actions or in a statement under 37 CFR 1.530, can be used in later litigation to limit claim scope.

These doctrines do not function like 315(e). They are case-by-case and require specific factual predicates. But practitioners who treat reexam as estoppel-free across the board sometimes get surprised in downstream litigation.

Why this matters more in 2025

The 2025 surge in third-party reexam filings is driven, in significant part, by the absence of 315(e)-style estoppel. Challengers migrating from IPR to reexam are explicitly choosing the procedure that does not constrain their downstream options. The shift is not just about cost or PTAB discretionary denial. It is about preserving optionality.

For practitioners on either side, the operating principle: the absence of statutory estoppel is not the absence of strategic consequence. The procedural record from a reexam is admissible, persuasive, and durable in any litigation that follows.